Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

100%

5 of 5 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 2

3(60.0%)

Phase 3

1(20.0%)

Phase 4

1(20.0%)

5Total

Phase 2(3)

Phase 3(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT01524705Phase 4Completed

FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)

Role: collaborator

NCT00831779Phase 2Completed

Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes

Role: collaborator

NCT00976495Phase 2Completed

Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes

Role: collaborator

NCT00683878Phase 3Completed

Add-on to Thiazolidinedione (TZD) Failures

Role: collaborator

NCT01498185Phase 2Completed

BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes

Role: collaborator

All 5 trials loaded